导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.39% | 1410/4773 |
| 近一周 | -3.55% | 4814/5465 |
| 近一月 | 0.73% | 455/5421 |
| 近一季 | 2.75% | 531/5231 |
| 近半年 | -3.06% | 2376/4920 |
| 近一年 | 5.14% | 1756/4394 |
| 近两年 | 28.54% | 2350/2954 |
| 近三年 | 22.28% | 1407/2253 |
| 成立以来 | 95.71% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.39% 524/4961 |
-10.21% 4074/5312 |
- - |
- - |
| 2025 | 4.12% 3072/4813 |
-2.58% 2917/3635 |
2.65% 1450/4076 |
2.75% 3781/4524 |
1.34% 1416/4813 |
| 2024 | 17.67% 661/3463 |
8.41% 186/2808 |
2.19% 385/3014 |
8.59% 2738/3129 |
-2.18% 1991/3463 |
| 2023 | 6.89% 159/2656 |
5.21% 814/2280 |
1.08% 243/2385 |
4.84% 121/2515 |
-4.14% 885/2655 |
| 2022 | -0.25% 38/2207 |
1.66% 97/1919 |
-0.44% 1624/2016 |
-2.00% 28/2113 |
0.58% 1482/2208 |
| 2021 | 15.24% 309/1822 |
4.60% 143/1255 |
8.40% 626/1330 |
3.24% 413/1466 |
-1.55% 1372/1822 |
| 2020 | - - |
- - |
- - |
9.22% 664/1164 |
3.76% 891/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时红利ETF VS. 长安沪深300非周期A(740101) |